Pérez-Zúñiga JM, Aguilar-Andrade C, Álvarez-Vera JL, Augusto-Pacheco M, Báez-Islas PE, Bates-Martín RA, Cervantes-Sánchez I, Espitia-Ríos ME, Estrada-Domínguez P, Jiménez-Alvarado R, Fermín-Caminero DJ, García-Camacho AS, Gómez-Rosas P, Grimaldo-Gómez FA, Guzmán-Mera P, Herrera-Olivares W, Martínez-Ramírez MA, Medina-Meza C, Mena-Zepeda V, Montoya-Jiménez L, Morales-Adrián JJ, Morales-Hernández AE, Mujica-Martínez A, Palma-Moreno OG, Reyes-Brena G, Reynoso-Pérez AO, Salazar-Ramírez Ó, Hernández-Ruiz E, Paredes-Lozano EP, Alvarado-Ibarra M

Language: Spanish
References: 19
Page: 174-188
PDF size: 500.24 Kb.

ABSTRACT

Nowadays, cancer have increased; non-Hodgkin lymphomas in Mexico represent the second cause of hematological malignancies, in addition, there are methods of staging the disease, risk and an approach to gene expression profiles by immunohistochemistry that have important implications in diagnosis, prognosis and treatment. Over time, the diagnostic instruments, equipment and techniques have been perfected, which allows the optimization of the results to establish the basic measures to subclassify the lymphomas by histological strain, phenotype B or T, degree of maturation, replication index as well as molecular characteristics and even differentiation algorithms. Once the variety and subtype of lymphoma are defined, there are other issues for the clinician, among which are the sites involved and with these sites, the optimal classification system, whatever it is, which allows optimizing the final results and predicting the possible outcomes in survival is this group of patients. The target of this document is to summarize the general characteristics to be considered in patients with non- Hodgkin lymphoma at the beginning of treatment; however, it should be remembered that advances in this medical area may generate controversies with this review and must dominate clinical reasoning and the medicine based on evidence in favor of the clinical benefit of the patients.

REFERENCES

1. Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. doi:10.1182/blood-2016-03-643544.

2. Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. doi:10.1182/blood-2016-01-643569.

3. Müller AMS, et al. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. doi:10.1007/s00277-004-0939-7.

4. Gómez-Dantés H, et al. The burden of cancer in Mexico, 1990-2013. Salud Púb Méx 2016;58(2):118-131.

5. Anderson T, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982;50(12):2699-2707.

6. Anderson T, DeVita VT, Simon RM, et al. Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 1982;50(12):2708-2721.

7. Gaulard P, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. World Health Organization, 2008;16

8. Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non- Hodgkin lymphoma: the Lugano classification. doi:10.1200/ JCO.2013.54.8800.

9. Portlock CS. Non-Hodgkin's lymphomas. Advances in diagnosis, staging, and management. Cancer 1990;65(3 Suppl):718-722.

10. Moormeier JA, et al. The staging of non-Hodgkin’s lymphomas. Semin Oncol 1990;17(1):43-50.

11. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG Avidity in lymphoma readdressed: A study of 766 patients. J Nucl Med 2010;51:25-30.

12. Ziepert M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. doi:10.1200/JCO.2009.26.2493.

13. Nooka AK, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. doi:10.1093/ annonc/mds429.

14. Kim SJ, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? doi:10.1093/annonc/mdp412.

15. Lee SM, et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. doi:10.1038/ sj.bmt.1701894.

16. Shipp MA, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. doi:10.1038/nm0102-68.

17. Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.

18. Henze J, et al. RECIST 1.1, irRECIST 1.1, and mRECIST: How to do. Current Radiology Reports 2016;4-48.

19. Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015;4:5.